General form of registration statement for all companies including face-amount certificate companies

6. Commitments and Contingencies (Details Narrative)

v2.4.1.9
6. Commitments and Contingencies (Details Narrative) (USD $)
3 Months Ended 6 Months Ended 12 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Sep. 30, 2014
Sep. 30, 2013
Mar. 31, 2014
Mar. 31, 2013
Potential severance under certain employment agreements     $ 1,130,000us-gaap_SeveranceCosts1      
Aggregated annual salaries under certain employment agreements 935,000us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent   935,000us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent      
Product revenue 2,695,000us-gaap_SalesRevenueGoodsNet 3,456,000us-gaap_SalesRevenueGoodsNet 5,491,000us-gaap_SalesRevenueGoodsNet 6,177,000us-gaap_SalesRevenueGoodsNet 10,894,000us-gaap_SalesRevenueGoodsNet 12,897,000us-gaap_SalesRevenueGoodsNet
Vetericyn and Innovacyn [Member]            
Product revenue 459,000us-gaap_SalesRevenueGoodsNet
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_VetericynAndInnovacynMember
1,289,000us-gaap_SalesRevenueGoodsNet
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_VetericynAndInnovacynMember
987,000us-gaap_SalesRevenueGoodsNet
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_VetericynAndInnovacynMember
2,030,000us-gaap_SalesRevenueGoodsNet
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_VetericynAndInnovacynMember
   
Accounts receivable 117,000us-gaap_AccountsReceivableGross
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_VetericynAndInnovacynMember
  117,000us-gaap_AccountsReceivableGross
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_VetericynAndInnovacynMember
  220,000us-gaap_AccountsReceivableGross
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_VetericynAndInnovacynMember
 
More Pharma [Member]            
Accounts receivable 1,201,000us-gaap_AccountsReceivableGross
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_MorePharmaMember
  1,201,000us-gaap_AccountsReceivableGross
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_MorePharmaMember
  790,000us-gaap_AccountsReceivableGross
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_MorePharmaMember
 
Transaction costs 16,000us-gaap_RelatedPartyTransactionAmountsOfTransaction
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_MorePharmaMember
16,000us-gaap_RelatedPartyTransactionAmountsOfTransaction
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_MorePharmaMember
32,000us-gaap_RelatedPartyTransactionAmountsOfTransaction
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_MorePharmaMember
32,000us-gaap_RelatedPartyTransactionAmountsOfTransaction
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_MorePharmaMember
   
Amortization of upfront fees (transaction costs) $ 378,000us-gaap_AmortizationOfDeferredCharges
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_MorePharmaMember
$ 378,000us-gaap_AmortizationOfDeferredCharges
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_MorePharmaMember
$ 752,000us-gaap_AmortizationOfDeferredCharges
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_MorePharmaMember
$ 752,000us-gaap_AmortizationOfDeferredCharges
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_MorePharmaMember